In vitro metabolism of misonidazole
- PMID: 7236487
- PMCID: PMC2010618
- DOI: 10.1038/bjc.1981.65
In vitro metabolism of misonidazole
Abstract
Misonidazole (MISO) is a nitroimidazole drug currently undergoing clinical trials as a radiosensitizer of hypoxic tumour cells. The drug is also toxic to such cells, probably because of metabolic activation of the nitro group under hypoxia. The metabolic fate of 14C-labelled MISO is examined, using hypoxic mammalian (CHO) cells in vitro. Organic-soluble and acid-soluble metabolites are formed, and radioactivity is bound to macromolecules. The organic-soluble products are separated by TLC and HPLC. Evidence is presented to show that one of the metabolites is hydroxylamino-misonidazole. The significance of metabolic nitroreduction is discussed.
Similar articles
-
Sulphydryls, ascorbate and oxygen as modifiers of the toxicity and metabolism of misonidazole in vitro.Br J Cancer. 1980 Jun;41(6):892-900. doi: 10.1038/bjc.1980.166. Br J Cancer. 1980. PMID: 7426314 Free PMC article.
-
Characteristics of the metabolism-induced binding of misonidazole to hypoxic mammalian cells.Cancer Res. 1983 Apr;43(4):1523-8. Cancer Res. 1983. PMID: 6831401
-
Binding to cellular macromolecules as a possible mechanism for the cytotoxicity of misonidazole.Cancer Res. 1980 Jul;40(7):2165-9. Cancer Res. 1980. PMID: 6155991
-
Metabolism induced binding of 14C-misonidazole to hypoxic cells: kinetic dependence on oxygen concentration and misonidazole concentration.Int J Radiat Oncol Biol Phys. 1984 Aug;10(8):1327-31. doi: 10.1016/0360-3016(84)90342-0. Int J Radiat Oncol Biol Phys. 1984. PMID: 6469755
-
Misonidazole and other hypoxia markers: metabolism and applications.Int J Radiat Oncol Biol Phys. 1986 Jul;12(7):1195-202. doi: 10.1016/0360-3016(86)90257-9. Int J Radiat Oncol Biol Phys. 1986. PMID: 3528089 Review.
Cited by
-
The Therapeutic Potential of Imidazole or Quinone-Based Compounds as Radiosensitisers in Combination with Radiotherapy for the Treatment of Head and Neck Squamous Cell Carcinoma.Cancers (Basel). 2022 Sep 27;14(19):4694. doi: 10.3390/cancers14194694. Cancers (Basel). 2022. PMID: 36230623 Free PMC article. Review.
-
Synthesis of Imidazole-Based Medicinal Molecules Utilizing the van Leusen Imidazole Synthesis.Pharmaceuticals (Basel). 2020 Mar 3;13(3):37. doi: 10.3390/ph13030037. Pharmaceuticals (Basel). 2020. PMID: 32138202 Free PMC article. Review.
-
Epigenetic modulation and apoptotic induction by a novel imidazo-benzamide derivative in human lung adenocarcinoma cells.Daru. 2021 Dec;29(2):377-387. doi: 10.1007/s40199-021-00419-3. Epub 2021 Oct 12. Daru. 2021. PMID: 34642906 Free PMC article.
-
Imidazoles as potential anticancer agents.Medchemcomm. 2017 Apr 13;8(9):1742-1773. doi: 10.1039/c7md00067g. eCollection 2017 Sep 1. Medchemcomm. 2017. PMID: 30108886 Free PMC article. Review.
-
Functionalized Nitroimidazole Scaffold Construction and Their Pharmaceutical Applications: A 1950-2021 Comprehensive Overview.Pharmaceuticals (Basel). 2022 Apr 30;15(5):561. doi: 10.3390/ph15050561. Pharmaceuticals (Basel). 2022. PMID: 35631389 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources